
| Pair Name | Silibinin, Doxorubicin | ||
| Phytochemical Name | Silibinin (PubChem CID: 31553 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Silibinin, Doxorubicin | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Down-regulation | Activity | CDK1 | hsa983 |
| Up-regulation | Expression | CDC25C | hsa995 | |
| Up-regulation | Expression | MS4A1 | hsa931 | |
| Up-regulation | Expression | CHEK1 | hsa1111 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| In Vivo Model | An orthotopic rat model of HCC was used, in which subcutaneously injected Morris hepatoma (MH)-3924A cells (5×10⁶) in syngeneic ACI rats (Harlan, USA) led to formation of a subcutaneous tumor within 14 days. | |||
| Result | Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study | |||
| No. | Title | Href |
|---|---|---|
| 1 | Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study. J BUON. 2016 Jul-Aug;21(4):917-924. | Click |